Clinical Trial Update: Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas [Phase 1]

View source ↗

Summary

A Phase I study of CEP-18770, a proteasome inhibitor, in patients with solid tumors and Non-Hodgkin lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• CEP-18770 (CEP-18770)

Snippet

Sponsor: Ethical Oncology Science | Conditions: Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED